Clinical Trial Update: Niraparib as First Line Therapy With Metastatic Homologous Repair-deficient Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating niraparib as first-line therapy for metastatic homologous recombination-deficient pancreatic cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Centre Leon Berard | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: TERMINATED